The Brief
Minos AI is a decentralized genomics platform built on Bittensor Subnet 107 — using an incentive-driven competitive framework to advance the accuracy of DNA variant calling, the process of identifying mutations from sequencing data.
The problem Minos addresses is a well-funded, unsolved one: despite significant investment from institutions including Google and the Broad Institute, no single variant-calling tool consistently outperforms others across all genomic contexts. As DNA sequencing costs have fallen dramatically, the bottleneck has shifted from generating data to analysing it with sufficient accuracy for clinical use.
The whitepaper needed to communicate a technically dense, multi-layered system to two distinct audiences: genomics researchers who understand the biology but may be unfamiliar with decentralised incentive systems, and Web3-native readers who understand Bittensor mechanics but have no genomics background.
What I Built
A comprehensive technical whitepaper covering the full Minos AI platform:
- Problem Framing — Clear, precise articulation of why variant calling remains an open problem, grounding the Minos approach in the real limitations of existing tools and the clinical stakes of improving accuracy
- HelixForge Methodology — Technical documentation of Minos’s synthetic mutation injection system — how challenge genomes are generated, how hidden mutations are embedded, and why this approach produces a more robust evaluation signal than static benchmarks
- Evaluation Framework — Documentation of the blind scoring system, multi-component accuracy metrics, and the EMA smoothing and Winner-Take-All incentive design that drives continuous optimisation from network miners
- Deployment Roadmap — Clear documentation of the five-phase deployment plan, connecting the technical milestones to the three value-creation outcomes: a validated synthetic genome database, a consensus variant caller exceeding individual tools, and accessible clinical infrastructure
- Audience Bridging — Layered explanations that allow both genomics experts and Bittensor-native readers to engage with the material at the depth they need, without either audience being forced through content irrelevant to their understanding
Approach
Whitepaper writing for a technically complex, dual-audience product is fundamentally a translation problem. The science has to be accurate enough to withstand scrutiny from domain experts. The system design has to be clear enough for a Web3 reader who has never encountered variant calling before. Neither audience should have to work hard to find what’s relevant to them.
The structure followed a deliberate progression: establish the problem in terms both audiences recognise, introduce the Minos mechanism with enough technical depth to be credible, then ground the roadmap in concrete, sequenced outcomes rather than abstract vision.
Every technical claim in the whitepaper was verified against the underlying system documentation and research context before it was written.
Results
A production whitepaper that communicates a genuinely novel approach to one of genomics’ hardest open problems — clearly enough for institutional stakeholders in hospitals, biobanks, and pharmaceutical companies to evaluate Minos AI’s infrastructure as a serious clinical candidate.